Target- |
MechanismInflammation mediator inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral TTI-0102 (as a potential treatment for COVID-19) compared to Cystagon® in Healthy Adult Male and Female Volunteers
A Multi-center, Randomized, Double-blind, Placebo-controlled, Study to Assess the Safety, Tolerability, Pharmacodynamics (PD) and Efficacy of TTI-0102 for the Treatment of Patients With Mild to Moderate COVID-19
This is multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics (PD) and efficacy of TTI-0102 for the treatment of patients with mild to moderate COVID-19. This is a phase 2 study of cysteamine-pantetheine disulfide (TTI-0102), an antiviral, anti-infectious, antioxidant and anti-CRS (cytokine release syndrome) investigational drug. Subjects will be randomized 2:1 to receive TTI-0102 or placebo daily for up to 14 days. Up to 5 centers in the US and Canada will conduct this study. 60 patients will be enrolled.
100 Clinical Results associated with Thiogenesis Therapeutics, Inc.
0 Patents (Medical) associated with Thiogenesis Therapeutics, Inc.
100 Deals associated with Thiogenesis Therapeutics, Inc.
100 Translational Medicine associated with Thiogenesis Therapeutics, Inc.